Blab Business
DKSH Partners with BridgeBio to Distribute ATTR-CM Treatment in Asia-Pacific
On June 11, 2026, DKSH Business Unit Healthcare announced a strategic distribution partnership with BridgeBio, a biotechnology company that develops therapies for genetic diseases. The agreement grants DKSH exclusive rights to distribute and commercialise BridgeBio’s transthyretin stabiliser, Attruby (acoramidis), in Australia, Singapore, South Korea and Taiwan.
Attruby is an oral medication that stabilises transthyretin, a protein that can misfold and form amyloid deposits in the heart. The drug treats cardiomyopathy caused by wild‑type or variant transthyretin‑mediated amyloidosis (ATTR‑CM) in adults. ATTR‑CM is a progressive, rare disease that leads to heart failure, frequent hospitalisations and premature death. While the drug received FDA approval in the United States in November 2024 and EU approval in February 2025, it has not yet been approved in the four markets covered by the partnership.
Under the terms of the agreement, DKSH will manage the entire commercialization chain—from regulatory affairs and medical affairs to market access, launch excellence and distribution. Leveraging its established infrastructure and expertise in complex healthcare systems, DKSH will support regulatory evaluation and, once approvals are obtained, make the treatment available to patients.
“BridgeBio’s scientific innovation combined with DKSH Healthcare’s end‑to‑end commercialization platform represents an important milestone,” said Patrik Grande, Global Head of Business Unit Healthcare at DKSH. “We are proud to launch this biotech innovation and expand access to important new treatment options reliably, responsibly, and at scale.”
BridgeBio’s focus on genetic diseases positions it to develop therapies that address unmet needs in rare disorders. Attruby’s development followed a phase‑3 ATTRibute‑CM study that enrolled more than 630 patients worldwide, demonstrating that the drug reduced cardiovascular death and cardiovascular‑related hospitalisation in adults with ATTR‑CM.
DKSH, headquartered in Switzerland, has long served as a market‑expansion partner for pharmaceutical, over‑the‑counter, consumer health and medical device companies. Its healthcare business unit offers integrated services that include regulatory support, medical affairs, market access and distribution. The partnership is intended to leverage these capabilities to bring a new treatment option to patients in the Asia‑Pacific region.
Because ATTR‑CM is underdiagnosed and has limited treatment options, the partnership could improve access for patients who currently rely on supportive care alone. The distribution agreement will be subject to local regulatory approvals in each country. DKSH will work with national authorities to navigate the approval process and ensure that the drug meets all safety, efficacy and quality requirements.
The collaboration also reflects a broader trend of biopharmaceutical companies partnering with distribution specialists to accelerate market entry in regions where regulatory pathways and supply‑chain logistics can be complex. By combining BridgeBio’s drug development expertise with DKSH’s commercial platform, the two companies aim to shorten the time between regulatory approval and patient access.
The partnership covers four key markets: Australia, Singapore, South Korea and Taiwan. Each of these countries has a robust healthcare infrastructure but also distinct regulatory frameworks. DKSH’s experience in navigating these systems will be critical to the successful launch of Attruby.
While the drug’s efficacy has been demonstrated in clinical trials, the partnership does not guarantee market approval. The product will still need to satisfy the regulatory authorities in each country, and reimbursement decisions will be made by local payers. DKSH’s market‑access team will engage with payers and health technology assessment bodies to secure coverage and reimbursement pathways.
In summary, the DKSH‑BridgeBio partnership is a strategic move to bring a novel ATTR‑CM therapy to patients in the Asia‑Pacific region. The agreement combines BridgeBio’s innovative drug with DKSH’s integrated commercialization capabilities, aiming to support regulatory evaluation, secure approvals and ultimately expand patient access to a treatment that addresses a significant unmet medical need.
The partnership will be monitored closely by clinicians, payers and patients as the drug moves through the regulatory process. Future updates will depend on the timing of approvals, reimbursement decisions and the launch of Attruby in the four markets.
Attruby is an oral medication that stabilises transthyretin, a protein that can misfold and form amyloid deposits in the heart. The drug treats cardiomyopathy caused by wild‑type or variant transthyretin‑mediated amyloidosis (ATTR‑CM) in adults. ATTR‑CM is a progressive, rare disease that leads to heart failure, frequent hospitalisations and premature death. While the drug received FDA approval in the United States in November 2024 and EU approval in February 2025, it has not yet been approved in the four markets covered by the partnership.
Under the terms of the agreement, DKSH will manage the entire commercialization chain—from regulatory affairs and medical affairs to market access, launch excellence and distribution. Leveraging its established infrastructure and expertise in complex healthcare systems, DKSH will support regulatory evaluation and, once approvals are obtained, make the treatment available to patients.
“BridgeBio’s scientific innovation combined with DKSH Healthcare’s end‑to‑end commercialization platform represents an important milestone,” said Patrik Grande, Global Head of Business Unit Healthcare at DKSH. “We are proud to launch this biotech innovation and expand access to important new treatment options reliably, responsibly, and at scale.”
BridgeBio’s focus on genetic diseases positions it to develop therapies that address unmet needs in rare disorders. Attruby’s development followed a phase‑3 ATTRibute‑CM study that enrolled more than 630 patients worldwide, demonstrating that the drug reduced cardiovascular death and cardiovascular‑related hospitalisation in adults with ATTR‑CM.
DKSH, headquartered in Switzerland, has long served as a market‑expansion partner for pharmaceutical, over‑the‑counter, consumer health and medical device companies. Its healthcare business unit offers integrated services that include regulatory support, medical affairs, market access and distribution. The partnership is intended to leverage these capabilities to bring a new treatment option to patients in the Asia‑Pacific region.
Because ATTR‑CM is underdiagnosed and has limited treatment options, the partnership could improve access for patients who currently rely on supportive care alone. The distribution agreement will be subject to local regulatory approvals in each country. DKSH will work with national authorities to navigate the approval process and ensure that the drug meets all safety, efficacy and quality requirements.
The collaboration also reflects a broader trend of biopharmaceutical companies partnering with distribution specialists to accelerate market entry in regions where regulatory pathways and supply‑chain logistics can be complex. By combining BridgeBio’s drug development expertise with DKSH’s commercial platform, the two companies aim to shorten the time between regulatory approval and patient access.
The partnership covers four key markets: Australia, Singapore, South Korea and Taiwan. Each of these countries has a robust healthcare infrastructure but also distinct regulatory frameworks. DKSH’s experience in navigating these systems will be critical to the successful launch of Attruby.
While the drug’s efficacy has been demonstrated in clinical trials, the partnership does not guarantee market approval. The product will still need to satisfy the regulatory authorities in each country, and reimbursement decisions will be made by local payers. DKSH’s market‑access team will engage with payers and health technology assessment bodies to secure coverage and reimbursement pathways.
In summary, the DKSH‑BridgeBio partnership is a strategic move to bring a novel ATTR‑CM therapy to patients in the Asia‑Pacific region. The agreement combines BridgeBio’s innovative drug with DKSH’s integrated commercialization capabilities, aiming to support regulatory evaluation, secure approvals and ultimately expand patient access to a treatment that addresses a significant unmet medical need.
The partnership will be monitored closely by clinicians, payers and patients as the drug moves through the regulatory process. Future updates will depend on the timing of approvals, reimbursement decisions and the launch of Attruby in the four markets.
